Show simple item record

dc.contributor.authorClamp, Aen_US
dc.contributor.authorAdams, Men_US
dc.contributor.authorAtkinson, Ren_US
dc.contributor.authorBoven, E.en_US
dc.contributor.authorCalvert, AHen_US
dc.contributor.authorCervantes, Aen_US
dc.contributor.authorGanesan, Ten_US
dc.contributor.authorLotz, Jen_US
dc.contributor.authorVasey, Pen_US
dc.contributor.authorCheverton, Pen_US
dc.contributor.authorJayson, GCen_US
dc.date.accessioned2011-11-14T14:38:46Z
dc.date.issued2004en_US
dc.identifier.citationGynecologic Oncology, 95(1), 114-9en_US
dc.identifier.issn0090-8258
dc.identifier.urihttp://hdl.handle.net/1871/26250
dc.description.abstractOBJECTIVES: There is an urgent need for new agents with activity in platinum- and taxane-resistant epithelial ovarian cancer. Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. A multicentre phase IIA study was conducted in patients with platinum- and taxane-resistant epithelial ovarian cancer. PATIENTS AND METHODS: Fifty-seven patients with bidimensionally measurable ovarian cancer, previously exposed to platinum and taxanes, whose disease had relapsed within 6 months of platinum-containing chemotherapy were randomised to one of two intravenous schedules of exatecan mesylate; 0.3 mg/m(2) daily for 5 days every 3 weeks (Arm A) or 2.1 mg/m(2) weekly for 3 weeks out of 4 (Arm B). RESULTS: There were no responses in the weekly arm and a radiological response rate of 5.3% (95% CI 0.3-21.8%) in the daily arm. Principal toxicities were myelosuppression and emesis. Grade 3/4 neutropenia occurred in 29% of patients in Arm A and 6% patients in Arm B. Seventy-one percent of patients in Arm A required red cell transfusions while on treatment. CONCLUSIONS: Exatecan is well tolerated in this poor prognosis group of patients but only has modest single agent activity when administered in a daily regimen.en_US
dc.relation.uri10.1016/j.ygyno.2004.06.047
dc.titleA phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.en_US
dc.typeArticle / Letter to editoren_US
dc.creator.metisIdVU1067021
dc.creator.metisIdVU1067022
dc.creator.metisIdVU1067023
dc.creator.metisIdVU1022206
dc.creator.metisIdVU1067024
dc.creator.metisIdVU1067025
dc.creator.metisIdVU1067026
dc.creator.metisIdVU1067027
dc.creator.metisIdVU1067028
dc.creator.metisIdVU1067029
dc.creator.metisIdVU1067030
dc.identifier.metisId170530
dc.provenance.metis2005-01-24 11:45
dc.source.volume95
dc.source.journalTitleGynecologic Oncologyen_US
dc.source.startpage114
dc.source.endpage9
dc.source.issue1
dc.creator.facultyVU medisch centrumnl_NL
dc.coverage.researchinstituteVUmc CCA 04nl_NL
dc.date.updated2014-02-07T10:38:42Z


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record